Cytochrome P450 2D-mediated metabolism is not necessary for tafenoquine and primaquine to eradicate the erythrocytic stages of Plasmodium berghei

Table 2 Primaquine (PQ) wild-type (WT) dose-ranging studies using C57BL/6 mice

Day dose administered^a	PQ dose (mg/kg)	No hepatic IVIS signal^b	No asexual erythrocytic infection (parasitemia)^c	No sexual erythrocytic infection (gametocytemia)^c
Causal prophylactic model
D0, D1	25 × 2d	5/5 (D1), 5/5 (D2)	5/5	NA
D0	10	5/5 (D1), 5/5 (D2)	3/5	NA
	20	5/5 (D1), 5/5 (D2)	5/5	NA
	40	5/5 (D1), 5/5 (D2)	5/5	NA
D1	40	1/5 (D1), 1/5 (D2)	0/5	NA
Erythrocytic treatment model
D4	10	NA	0/5	0/5
	20	NA	0/5	0/5
	40	NA	0/5	0/5

PQ primaquine, mg/kg milligrams free base of drug per kg body weight, NA not applicable, IVIS in vivo imaging system
^aDay of drug administration relative to intravenous sporozoite (IV SPZ) challenge (day 0) using C57BL/6 wild-type mice
^bNumber of animals without an IVIS signal (indicates no hepatic infection). D1 day 1 (relative to IV SPZ challenge day 0). D2 day 2 (relative to IV SPZ challenge day 0)
^cNumber of animals without parasitemia (flow cytometry) or gametocytemia (microscopy) day 29. N = 5 animals per cohort

ISSN: 1475-2875